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doi:10.1016/j.ejvs.2008.11.027Abstract Objectives: The aim of this study was to evaluate a possible correlation between
plasma levels of interleukin-6 (IL-6), metalloproteinase-9 (MMP-9) and C-reactive protein
(CRP) and the expansion of small abdominal aortic aneurysms (AAAs).
Design: Patients were selected from a prospective randomised clinical trial and categorised in
two groups, in which one group received active treatment (azithromycin) and the other
received placebo. No statistical difference in the expansion rate of AAAs between the groups
was found and the two groups were considered as one cohort in the present study.
Material and methods: In this study, 213 patients with AAAs between 35 and 49 mm were fol-
lowed-up with ultrasound examination every 6th month. Blood samples were taken on two
occasions (6 months apart). IL-6 and MMP-9 were analysed on one occasion using Quantikine
analysing kits (R&D Systems, Inc., USA). CRP was analysed using sensitive-CRP method.
Results: Levels of IL-6, MMP-9 and CRP did not correlate with AAA expansion. Neither was there
any correlation between statin medication and changes in MMP-9 levels over the 6-month
period. Patients on statins had a lower expansion rate than those not taking statins: 0.16 versus
0.25 cm per year.
Conclusion: No correlation was found between levels of circulating IL-6, MMP-9, CRP and the
expansion of small-diameter AAAs, indicating no clinical use of these markers in AAA
surveillance.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved., M.D., Department of Surgical Sciences, Section of Vascular Surgery, Uppsala University Hospital,
26154000; fax: þ46 26154295.
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inflammation are considered important in the pathogenesis of
abdominal aortic aneurysms (AAAs).1,2 Experimental studies
of elastase-induced aneurysms indicate that an inflammatory
reaction within the aortic media is crucial for aortic dilata-
tion.3 A human biopsy study has confirmed the association
between the extent of inflammation of the aortic wall and
aortic diameter.4 Interleukin-6 (IL-6), metalloproteinase-9
(MMP-9) and C-reactive protein (CRP) are markers of inflam-
matory processes and have all been associated with AAA
pathogenesis, while also being easy to analyse in peripheral
blood samples. Presuming the importance of inflammation in
AAA expansion, it is tempting to assume that there may be
a correlation between plasma levels of these substances and
expansion rate. IL-6 is one of the pro-inflammatory cytokines
mediating MMP-9 expression and stimulation of CRP produc-
tion.5 Moreover, AAA may be an important source of circu-
lating IL-6.6 MMP-9 is associated with the expansion of AAA
shownboth in in vitroand in vivo studies,4,7,8 and interestingly
MMP-9might be suppressed by statins.9e11 CRP levelsmight be
higher inpatientswithAAAascomparedtopatientswithaortic
occlusive disease.12 It has also been suggested that there is an
association between serum levels of CRP and AAA size.13
This study aimed to evaluate the correlation (if any)
between circulating levels of IL-6, MMP-9 and CRP and the
expansion of small-diameter AAAs.
Materials and Methods
This study included 213 patients with an AAA diameter of
35e49 mm selected from a clinical trial conducted between
May 2002 and August 2005. Of these patients, one group
received active treatment (azithromycin) and the other
received placebo. This study aimed to examine the effect
of azithromycin on the expansion of small-diameter AAAs.
Patients were recruited from the AAA surveillance pro-
gramme. Exclusion criteria were: AAA <35 mm or AAA
50 mm, age >81 years, intolerance to macrolide antibi-
otics, creatinine clearance <40 mlmin1 and medication
with ergotamine. As there was no statistical difference in
the expansion rate of the AAAs between the groups, both
groups are considered as a single cohort in the present
study. Ultrasound examination was carried out in a stand-
ardised way every 6th month for a minimum of 18 months.
The widest antero-posterior diameter was measured in
both axial and transverse angles. Medical history, current
medication and smoking habits were recorded. Blood
samples were taken on two occasions e at inclusion and 6
months after joining the study. Plasma was stored at 70 C
until analysis of IL-6, MMP-9 and CRP. Plasma samples for IL-
6 (182 patients) and MMP-9 (196 patients) were analysed at
a single occasion using Quantikine analysing kits (R&D
Systems, Inc, USA). Plasma samples from 198 patients were
analysed for CRP using CRP a-Tina-quant (Roche/ Hitachi,
Germany). All samples were assayed in a single batch, and
were run in duplicates.
Statistical Analysis
Categorical variables were summarised by percentages and
counts and continuous variables by medians and inter-measurements, the average expansion rate of the AAA
diameter was estimated through a linear regression model.
For IL-6, MMP-9 and CRP, an average change of the log level
of the concentration was estimated in a similar way with
a linear regression model for each patient. The number of
patients with decreasing, unchanged or increasing levels
were summarised. To compare the expansion rate of the
AAA with the change in levels of the different markers,
Spearman correlation coefficients were calculated from the
individually estimated slopes. The WilcoxoneManneWhit-
ney test was used for comparing expansion rates between
groups. Confidence intervals were calculated using the
percentile method on 10 000 bootstrap samples. All statis-
tical analyses were done using R version 2.5.2.14
Ethics
All patients gave their written consent after being provided
with complete information about the study. The study was
approved by the Committee of Ethics of Uppsala University
(Dno; 01-349).
Results
Every 6th month, 213 patients were followed-up by ultra-
sound examination. The median AAA diameter at inclusion
was 4.0 cm (range: 3.7e4.4 cm). The median age was 71
years, and 76.5% of the subjects were men. As seen in Table
1, this cohort is representative for patients with AAA. The
low number (5.6%) of patients with chronic obstructive
pulmonary disease (COPD) is probably because the diag-
nosis was confirmed only by oral confession. Most patients
had atherosclerotic manifestations, of which 58.7%
suffered hypertension and 85 patients (39.9%) were on
medication with statins. The mean annual AAA expansion
rate was 0.25 cm. Levels of IL-6 were unchanged in nine
(4.9%), decreased in 83 (46%) and showed an increase in 90
(49%) patients. MMP-9 levels were unchanged in two (1%)
patients, 112 (57%) showed a decrease and 82 (42%) an
increase, and CRP levels were unchanged in three (1.5%)
patients, while 106 (54%) showed a decease and 89 (45%) an
increase over the 6-month period (Table 2). No correlation
was found between plasma levels of IL-6, MMP-9 and CRP
and the expansion of small-diameter AAAs, irrespective of
azithromycin treatment (Tables 2 and 3). The correlations
for the 6 months studied between AAA expansion and the
parameters were: IL-6 e rZ 0.08, pZ 0.31; MMP-9 e
rZ 0.09, pZ 0.19 and CRP: rZ0.03, pZ 0.70. There
were no differences between patients on statin medication
and those not on statin medication regarding changes in
MMP-9 levels over the 6-month period studied. However, 85
patients on statin medication had a lower median expan-
sion rate than 127 patients not taking statins (0.16 versus
0.25 cm per year, WilcoxoneManneWhitney p-value: 0.008,
95% bootstrap confidence interval for the difference:
0.003e0.15). Among non-smokers and smokers, 44% and
34% were on statins, respectively. No change in anti-
inflammatory medication was reported, although seven
patients had ceased smoking after 18 months into the
study.
Table 1 Baseline characteristics.
N
Age (years), median (IQR) 213 71 (67e75)
Gender (male) 213 76.5 (163)
Weight (kg), median (IQR) 210 78 (70e87)
Length (cm), median (IQR) 207 174 (169e180)
History of MI (%) (N ) 213 31 (66)
History of stroke (%) (N ) 213 14.1 (30)
Asthma (%) (N ) 213 3.8 (8)
COPD (%) (N ) 213 5.6 (12)
Smoking (%) (N ) 213 37.6 (80)
Heredity (%) (N ) 211 13.3 (28)
Previous vascular
surgery (%) (N )
213 27.7 (59)
Diabetes (%) (N ) 213 4.2 (9)
Hypertension (%) (N ) 213 58.7 (125)
Azithromycin (%) (N ) 213 49.8 (106)
Statins (%) (N ) 213 39.9 (85)
ASA (%) (N ) 212 47.6 (101)
ACE inhibitors (%) (N ) 212 29.7 (63)
MMP-9, median (IQR) 208 316 (205e474)
IL-6, median (IQR) 200 2.66 (1.56e4.49)
CRP, median (IQR) 211 2.95 (1.21e6.71)
Ultrasound (cm) median (IQR) 213 4.0 (3.7e4.4)
kgZ kilogram, cmZ centimeter, MIZmyocardial infarction,
COPDZ chronic obstructive pulmonary disease, vasc. opZ
vascular operation (does not include CABG or PCI).
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The present study examined the correlation between
circulating levels of IL-6, MMP-9 and CRP, all markers of
inflammation, and the expansion of small-diameter AAAs
over a 6-month period. IL-6, MMP-9 and CRP have all been
associated with AAA pathogenesis. Presuming the impor-
tance of inflammation in AAA expansion, it is tempting to
suggest a correlation between plasma levels of these
substances and the expansion rate. Circulating IL-6 has
been detected in significantly higher concentrations in AAA
patients, compared to patients with either coronary heart
disease or healthy controls.15 Patients detected with earlyTable 2 Changes in IL-6, MMP-9 and CRP levels over a
6-month period.
Decreasing Unchanged Increasing
N (%) N (%) N (%)
IL-6 83 46 9 5 90 49
Placebo 43 48 3 3.4 43 48
Azithromycin 40 43 6 6.5 47 50
MMP-9 112 57 2 1 82 42
Placebo 50 53 1 1.1 43 46
Azithromycin 62 54 1 1.0 39 38
CRP 106 54 3 2 89 45
Placebo 52 54 0 0 45 46
Azithromycin 54 54 3 3 44 44aortic dilatation may have increased serum levels of IL-6,16
indicating that inflammation might be of importance in
early AAA formation. IL-6 is found in high concentrations in
aneurysmal-wall biopsies,5,17 and AAAs seem to be a source
of circulating IL-6.6 However, Jones et al.6 could not detect
any association between IL-6 levels and the growth rate.
Furthermore, IL-6 has a central role in the acute-phase
response stimulating elevation of MMP-9 and CRP levels and
in the activation of B and T lymphocytes. Over the years,
a body of evidence has grown in favour of an association
especially between MMP-9 e and AAA pathogenesis. MMP-9
can be analysed not only in tissue biopsies but also in
peripheral blood samples. It has been proposed that MMP-9
may be a marker for inflammation.18 Patients with AAA
have higher levels of MMP-9 in peripheral blood samples
than patients with aortic occlusive disease (AOD) and
healthy volunteers,19,20 indicating that MMP-9 may serve as
a marker for tissue metabolism in patients with AAA. Organ
culture studies suggest that aneurysmal tissue is the source
of MMP-9,3,21,22 and interestingly Pyo et al. reported that
MMP-9-deficient mice were aneurysm resistant, as opposed
to MMP-12-deficient mice, indicating MMP-9 as a crucial
enzyme in AAA formation.8 A number of studies show an
association between the expansion of AAAs and MMP-9
levels and indications that larger aneurysms have higher
levels of MMP-9 as compared to smaller AAAs.4,7,23,24 It has
been proposed that high MMP-9 activity in the AAA wall is
associated with rupture.25 There may be a difference in
MMP-9 activity between males and females, with lower
activity in females, supporting gender-related differences
in AAA formation as demonstrated in an experimental AAA
model.26 The use of statins is increasing, and there are
indications that statins may attenuate/suppress MMP-9
activity.9e11 However, no such effect was detected in the
present study. Interestingly, no statistical difference was
detected in baseline MMP-9 levels between statin and non-
statin users, indicating that statin medications do not alter
MMP-9 levels in plasma (data not shown). Others have used
in vitro tissue analysis, whereas we have used peripheral
blood which might explain the contradictory results. CRP
has emerged as a risk factor for atherosclerosis and its
progression.27e29 Powell et al.12 reported that serum CRP
was elevated in patients operated on for AAA as compared
to patients operated for AOD. Furthermore, patients with
AAA have higher CRP levels in serum than controls without
AAA,30 although CRP may not be associated with rapid
expansion.31 There are studies where a significant elevation
of CRP has been found in symptomatic, or even ruptured,
AAAs as compared to asymptomatic AAAs.32,33 Moreover,
CRP might be, in at least some patients, produced by
aneurysmal and atherosclerotic tissue e that is, macro-
phages and smooth muscle cells, underscoring the inflam-
matory nature of AAA.13,34 The expansion pattern of AAAs
has been estimated to be about 10% per annum.35e38
Although this is not applicable for the individual AAA
patient, it is well known among clinicians that there are
large individual variations in expansion patterns, with
episodes of rapid expansion that may be followed by
periods of slower, or even cessation of, expansion. It would
be of interest to find a marker for identifying aneurysms
with progressive growth that indicates a necessity for
treatment. Markers of inflammatory processes could be of
Table 3 Correlation matrix between changes in the size
of the AAA and levels of MMP-9, CRP and IL-6.
AAA MMP-9 CRP IL-6
AAA 0.19 0.70 0.31
MMP-9 0.09 0.02 0.22
CRP 0.03 0.17 <0.01
IL-6 0.08 0.09 0.51
Values below the diagonal show the Spearman correlation
coefficient and values above the diagonal the corresponding
p-values for the test of no correlation.
AAA Expansion and Plasma Levels of IL-6, MMP9, CRP 423interest, both from the expansion point of view and as
targets for novel pharmacological therapy in minimising
growth.
Undoubtedly, patients with an AAA have higher levels of
IL-6, MMP-9 and CRP than patients with either AOD, coro-
nary heart disease or in healthy volunteers, indicating an
on-going inflammatory process in patients with AAA. We
could not, however, detect a correlation between levels of
circulating IL-6, MMP-9, CRP and the expansion of small-
diameter AAAs, indicating several possibilities: the inflam-
mation is persistent or low active, that is, no dramatic
changes over time; the process might be ‘cold’ or
secondary to e for instance, hypoxia e and might not
release IL-6, MMP-9 or CRP into the circulation. The
strength of this study is the relatively large sample size,
although hampered by the retrospective nature of the
study.
In conclusion, we state that there is no clinical use of
these markers (IL-6, MM-9 and CRP) in AAA surveillance.
Ultrasound examination remains the surveillance tool of
choice. We could not establish a correlation between the
use of statins and plasma levels of MMP-9. Patients on
statins had a lower expansion rate than those not on sta-
tins. This finding warrants further studies.
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